BioGenomics is a Science driven enterprise. Led by eminent scientists, business professionals and a focussed team of molecular biologists, microbiologists and protein engineers, BioGenomics has, in a short span of 10 years, developed dozens of Biopharmaceuticals and Biotech products.
BioGenomics has a thorough understanding of both microbial and mammalian technologies and the ability to develop own clones and cell lines. The resulting unique platform technology has allowed BioGenomics to rapidly deliver efficient, cost-effective, scalable and internationally acceptable technologies and products.
With fully integrated ‘Bench to Manufacturing’ facilities, BioGenomics ensures a quick turnaround, adaptive technology and is capable of full-scale manufacturing.
BioGenomics is consistently able to meet and exceed all regulatory standards in its products, processes and facilities.
Our proven capability to research, develop, customize and manufacture high-value biopharmaceuticals is an endorsement of our ability to meet global benchmarks. Our strengths lie in our scientific forte, proprietary technologies and state-of-the-art facilities.
BioGenomics has a strong scientific base, and we aim to innovate and adapt to the changing socio-economic demands of healthcare, at every stage, from laboratory bench to manufacturing shop floor.
Young, rapidly growing biopharmaceutical firm, BioGenomics is on a trajectory of delivering excellence in healthcare. We draw from our core desire of wanting to enrich lives with high-quality and valuable drugs. Our mission is to deliver affordable healthcare and to do all we can to ensure patient access to expensive specialty pharmaceuticals and biological drugs.
We are here to deliver on the promise that all advances on the laboratory bench, intellectual capital and investment in the life sciences are all pillars of support for a single purpose – the patient's wellbeing.
In keeping this ideal in mind BioGenomics was founded with the belief that affordable healthcare is a thing of the past in the developed world and a false- promise for the developing world. Extremely high-priced specialty drugs and biologicals have combined with complex global healthcare delivery systems to cause cost escalation to an extent that healthcare systems are strained and bursting at the seams in the developed world. On the other hand, patients in developing countries have poor access to valuable pharmaceutical products.
Biosimilars offer the world a unique opportunity to simultaneously increase healthcare delivery while also shaving tens of billions of dollars every year in healthcare spend. We think Biosimilars adoption is a sensible way forward to achieve our mission.
BioGenomics aims to redress the balance by providing high-value drugs to patients at affordable prices. To that extent we have embarked on an ambitious drug-development program around Biosimilars and have charted a plan based on a highly-streamlined and efficient technology platform and manufacturing process to deliver 15 Biosimilars over the next few years.
- To deliver high quality products through a safe and compliant environment with advanced infrastructure.
- To make affordable healthcare to all patients.
- To develop an enriching relationship with our customers, employees and partners.
- To develop innovative products, technologies and business practices.
Established by our top management, which consists of eminent scientists, our culture promotes continuous scientific exploration and innovation. There is no limit to the possibilities of life-changing breakthroughs that we can discover.
High Quality Products and Services
Through adherence to strict processes, regulations, safety norms and extensive testing, we ensure our products are clinically safe and highly effective.
Adaptive Innovation in a Fully-Integrated Business Model
We operate a fully integrated business. Hence, from bench research and development to actual large scale manufacturing, we do it all. Since both the products and the technologies used to manufacture them, are in-house, turnaround is quick and high-level of customisation is possible.
Our board members are highly trained and experienced in their fields. Their in-depth knowledge and focus contributes to the robustness of our processes and ensures our projects are carried out successfully without any glitches.
Completely ‘Animal Origin Free’ Products
Our products are 100% Animal Origin Free. They ensure complete freedom from complications and diseases arising from animal-based drugs and meet stringent international regulations. Our strengths lie in our scientific forte, proprietary technologies and state-of-the-art facilities.
Board of Directors
Mr.Parakh is a highly experienced and respected business professional and is considered a visionary amongst his peers. He currently holds the position of Managing Director, Finance, Saud Bahwan Group, Muscat (Oman). His dynamic leadership over three decades has played a key role in the success of the firm and its rise . Read more
Over the last more than three decades, he has successfully displayed the best of his dynamism and visionary leadership in one of the largest trading houses in the Middle East, with an annual turnover of US$ 5 billion. Mr. Parakh has played a key role in growth of India-Oman bilateralism. He is also a supporter of several humanitarian causes. Mr. Parakh is an icon in the expatriate Indian business community. Mr. Parakh trained as a Chartered Accountant before embarking on a career in management. He obtained his Chartered Accountancy in 1971 from the Institute of Chartered Accountants of India (ICAI), Bombay. Close Bio
Dr. Barwani is the Founder and Chairman of the MB Holding Group, a holding company with diverse interests. Dr. Barwani founded MB Petroleum Services in 1986 in Oman. He has a background in the Oil and Gas industry and began his career as a Reservoir Engineer at PDO (1976-86) (a joint venture between Shell and the Government of Oman). Read more
Dr. Barwani is on the Board of several joint stock companies in Oman includingTransgulf Investment Holding Company (Chairman), Al Madina Gulf Insurance Co. (Chairman), Oman Aviation Services Co. Dr. Barwani was on the Board of Directors of the National Bank of Oman (1997-2005), Taageer Investment & Leasing Co. (2001-2005) and Shell Oman Marketing Co. SAOG (2001-2006). He has also held the position of Regional Vice President of the International Association of Drilling Contractors. He is an active member of the Oman- India business association and spearheads several bilateral efforts. He holds a Bachelor’s Degree in Science from Miami University, Ohio, USA, and a Master’s degree in Petroleum Engineering from Herriott-Watt University, Edinburgh, UK. Close Bio
Mr. Usama is Director, Business Development in MB Holding Group and is responsible for new projects and the investments. He is also actively involved in the MB Group's trading business. Read more
He is currently on the Board of Directors of Ahli Bank SAOG, a commercial bank in Oman; Taager Finance Company SAOG, an independent leasing entity; and is Chairman of Flexible Industrial Packaging Co. SAOG all of which are publicly traded on the Muscat Securities Market. Mr. Barwani has a degree in Petroleum Engineering from Tulsa University (USA) and a Master’sdegree in Energy, Trade and Finance from City University, London. He was with Daleel Petroleum for two years before joining the MB Group. Close Bio
Mr. Srivastava is the Chief Financial Officer of MB Holding Group, which he joined in 2001. He has over 23 years of experience in corporate finance, M&A, project finance and structuring. He worked with premier financial institutions and merchant bankers in India for eight years playing key roles in in project financing, financial due diligence, economic modelling, advisory services and initial public offerings. Read more
For the last 13 years he has worked out of Oman, identifying and appraising investment opportunities in the region, advising on acquisitions, business structuring, negotiating deals, arranging finance through international banks and institutions and advising on treasury management. He is also on the board of Flexible Industrial Packaging Co. and Interior Hotels Co. SAOG, public companies that are listed on the Muscat Securities Market. Mr. Sushil is a graduate in Chemical Engineering, has a Master’s degree in Finance (AICWA) and a post graduate diploma in computers. Close Bio
Dr. Sonar is one of the Founder-Directors of BioGenomics. His core expertise lies in protein engineering with special emphasis on process scale protein folding, protein purification, protein characterization and downstream process optimizations for Biologics. He has successfully completed downstream process development work for over a dozen microbial and human products. Prior to BioGenomics, he was one of the Founder-Directors of Molecular Diagnostics Pvt. Ltd, India’s first private-sector diagnostic laboratory exclusively focused on molecular pathology. Read more
Dr. Sonar has a Ph.D. from the Indian Institute of Technology (IIT) Powai, Mumbai in Protein Engineering and Purification. He did his post-doctoral work with Dr. Kenneth Rothschild, Boston University where he also worked in a close collaboration with Prof. Har Gobind Khorana, Nobel laureate at Masschusetts Institute of Technology (MIT). Dr. Sonar has over 25 publications to his credit in journals such as Nature and Proc. Natl. Acad. Sci., and also holds over 20 patents. Close Bio
Dr. Archana is one of the Founder-Directors of BioGenomics. She has over 15 years of experience in molecular biology and protein science. Her core expertise is in molecular biology, strain development for biopharmaceuticals and the upstream production in biopharmaceutical manufacturing and scale-up. She has successfully completed strain development and upstream process development for over a dozen Microbial and Mammalian products. She has developed novel platform technologies for the development and production processes at BioGenomics. She has several related patents and publications to her credit. Read more
Prior to BioGenomics, Dr. Archana Co-founded Molecular Diagnostics Pvt. Ltd, India’s first private-sector diagnostic laboratory exclusively focused on molecular pathology. She has been largely responsible for development of more than 190 diagnostic products at MDPL across several specialities including infectious diseases, cancer and genetically inherited disorders. Dr. Archana has a Masters in Biochemistry from MS University of Baroda, where she was the university gold medalist. She obtained her doctorate from the Center of DNA Fingerprinting and Manipal University. Close Bio
Dr. Sonar is one of the Founder-Directors of BioGenomics. His core expertise lies in Protein engineering with special emphasis on Process scale protein folding, Protein Purification, Protein Characterization and Downstream Process Optimizations for Biologics. He has successfully completed Downstream Process Development work for over a dozen microbial and human products. Prior to BioGenomics, he was one of the Founder-Directors of Molecular Diagnostics Pvt. Ltd, India’s first private-sector diagnostic laboratory exclusively focused on Molecular Pathology. Read more
Sanjay has a Ph.D. from the Indian Institute of Technology (IIT) Powai, Mumbai in Protein Engineering and Purification. He did his post-doctoral work with Dr. Kenneth Rothschild, Boston Universtity where he also worked in a close collaboration with Prof. Har Gobind Khorana, Nobel Laurate at Masschusetts Institute of Technology (MIT). Dr. Sonar has over 25 publications to this credit in journals such as Nature and Proc. Natl. Acad. Sci., and also holds over 20 patents. Close Bio
Archana is one of the Founder-Directors at BioGenomics. She has over 15 years of experience in molecular biology and protein science. Her core expertise is in Molecular Biology, Strain Development for Biopharmaceuticals and the Upstream Production in Biopharmaceutical manufacturing and scale-up. She has successfully completed strain development and Upstream Process Development for over a dozen Microbial and Mammalian products. She has developed Novel Platform technologies for the development and production processes at BioGenomics. She has several related patents and publications to her credit. Read more
Prior to BioGenomics, Archana Co-founded Molecular Diagnostics Pvt. Ltd, India’s first private-sector diagnostic laboratory exclusively focused on Molecular Pathology. She has been largely responsible for development of more than 190 diagnostic products at MDPL across several specialities including infectious diseases, cancer and genetically inherited disorders. Archana has a Masters in Biochemistry for MS University of Baroda, where she was the University Gold Medalist. She obtained Ph.D. from the Center of DNA Fingerprinting and Manipal University. Close Bio
Mr. Abhishek is a Senior Manager and a core member of the management team since the firm’s inception. He has over 12 years of national and international experience. Over the last few years, he has developed core expertise in management of finances, accounting and admintistration of biopharmacuetical research and manufacturing. Read more
He has played a pivotal role in building large facilities related to biopharmaceutical manufacturing and has in-depth insights from finance and management perspectives. He is currently in charge of Finance & Accounting, Operations & Administration of the company. Prior to BioGenomics, he was a founder-member of Molecular Diagnostics Pvt. Ltd, India’s first private-sector diagnostic laboratory focused on Molecular Pathology. Mr. Abhishek is a Chartered Accountant and has studied management from IIM Kolkata. Close Bio
Dr. Vikram is the Business Advisor to BioGenomics, leading the development of global commercialization, licensing and partnering strategies for the firm. As a consultant at PriceSpective, a global value strategy consultancy, Dr. Vikram has worked with a variety of large pharmaceutical and biotech clients on global commercialization strategies for drug launches, due-diligence for in-licensing and out-licensing of development stage drugs and M&A. Read more
Dr. Vikram’s out-licensing portfolio charge includes drugs spanning a wide range of therapeutic areas and development stage. Dr. Vikram has worked as a consultant providing technical and commercial evaluations in areas of gene knockdown, genomics, genetics and for drugs in various therapeutic areas, serving a diverse clientele including pharmaceutical, biotech and federal entities. Dr. Vikram was a Research Specialist at the Howard Hughes Medical Institute where he performed studies in respiratory neurobiology. Vikram has a PhD in Genetics from the University of Sheffield, graduate training from the University of Cambridge and postdoctoral training from Stanford University.Dr. Vikram is an INLAKS scholar (India) and has received numerous fellowships including a Wellcome Trust Fellowship (UK), Damon Runyan Cancer Fellowship (USA) and a Human Frontier Sciences Program award (France). Close Bio